Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Exelixis Inc (NQ: EXEL ) 25.88 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Exelixis Inc < Previous 1 2 3 4 5 6 7 8 9 ... 13 14 Next > Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update November 01, 2023 From Exelixis, Inc. Via Business Wire Earnings Outlook For Exelixis October 31, 2023 Via Benzinga 4 Dominant Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip October 28, 2023 Bargains abound for growth-seeking investors, with the Nasdaq Composite still 20% below its record-closing high. Via The Motley Fool Topics Stocks Exposures US Equities Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030 October 25, 2023 EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END Via FinancialNewsMedia Is Exelixis Stock a Buy Now? October 18, 2023 There is one key reason to consider the stock. Via The Motley Fool 14 Analysts Have This to Say About Exelixis October 11, 2023 Via Benzinga Why Exelixis Stock Is Trading Lower Today October 23, 2023 Exelixis, Inc. (NASDAQ: EXEL) shares are trading lower on Monday after the company announced detailed results from its Phase 3 CABINET pivotal trial evaluating Cabozantinib in Via Benzinga Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023 October 22, 2023 From Exelixis, Inc. Via Business Wire 3 Under-the-Radar Biotech Stocks to Buy in 2023 October 19, 2023 These three lesser-known biotech companies are profitable and growing revenue. Via The Motley Fool Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023 October 18, 2023 From Exelixis, Inc. Via Business Wire 2 Top Biotech Stocks Defying the Bear Market September 15, 2023 The best may be yet to come for these companies. Via The Motley Fool The Latest Analyst Ratings for Exelixis September 13, 2023 Via Benzinga Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation. October 13, 2023 EXELIXIS INC (NASDAQ:EXEL) is showing good growth, while it is not too expensive. Via Chartmill Steady Eddies: 3 Low Beta Stocks for Long-Haul Gains October 02, 2023 Low-beta stocks provide an avenue for investors looking for long-term growth accompanied by low volatility. Via InvestorPlace 10 Health Care Stocks With Whale Alerts In Today's Session September 29, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2023 September 26, 2023 Via Benzinga Where Exelixis Stands With Analysts August 22, 2023 Via Benzinga 3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall September 20, 2023 Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy. Via InvestorPlace Week In Review: Hasten Signs $325 Million Deal For China Rights To PCSK9 Cholesterol Therapy September 16, 2023 Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor from LIB Therapeutics. Meanwhile, Insilico Medicine out-licensed global rights to a small molecule... Via Talk Markets 4 Magnificent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip September 16, 2023 A 14% decline in the Nasdaq Composite represents the perfect opportunity for investors to pounce. Via The Motley Fool Topics Stocks Exposures US Equities Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor September 12, 2023 From Exelixis, Inc. Via Business Wire Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September August 31, 2023 From Exelixis Via Business Wire The Top Healthcare Stocks to Buy With $100 August 30, 2023 Both stocks have outperformed the broader market in the last 12 months. Via The Motley Fool Exelixis Inc. (NASDAQ: EXEL) Sets New 52-Week High in Tuesday Session August 29, 2023 Via Investor Brand Network Exelixis' Lead Cancer Treatment Delivers Another Surprise, Though Analyst Finds Commercial Opportunity In Pancreatic Neuroendocrine Modest August 24, 2023 Thursday, Exelixis Inc (NASDAQ: EXEL) announced that the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board (DSMB) unanimously recommended to unblind and stop the... Via Benzinga Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors August 24, 2023 From Exelixis, Inc. Via Business Wire 2 No-Brainer Biotech Stocks to Buy Right Now August 24, 2023 These two companies make a compelling case for a high price. Via The Motley Fool Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer August 23, 2023 From Exelixis, Inc. Via Business Wire These Are the ONLY 3 Biotech Stocks to Consider in August 2023 August 21, 2023 These biotech stocks to buy represent tremendous bets and are essentially fueling innovation and portfolio growth at the same time. Via InvestorPlace Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients August 21, 2023 Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 13 14 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.